Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.
According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.
The startup has released beta versions of two targeted sequencing panels, one covering somatic mutations associated with lung and colon cancers, and another for BRCA1 and BRCA2 germline mutations. Additional information about beta users of these panels and their content and methodology were not disclosed.
The investment will help Pillar continue its R&D efforts in tissue-based sequencing panels, as well as support efforts to develop new liquid biopsy products, the firm said.
Source: https://www.genomeweb.com/molecular-diagnostics/cancer-dx-firm-pillar-biosciences-gets-18m-investment-ori-healthcare#.Y8jx8nZByUn
Related Posts
FDA Approves IND for LAE120, a Novel USP1 Inhibitor for Advanced Solid Tumors (March 4, 2025)
In March 2025, Laekna announced that the FDA approved the IND for LAE120, a novel USP1 inhibitor developed internally for advanced solid tumors. LAE120 shows potent monotherapy anti-tumor activity and synergy with PARP inhibitors, especially in homologous recombination deficiency (HRD) cancers. It demonstrated strong tumor inhibition in various xenograft models
Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)
In September 2024, Pillar Biosciences announced a strategic partnership with AstraZeneca to expand laboratory access to molecular testing in Europe and the UK using rapid, affordable NGS-based liquid biopsy tumor profiling kits. The collaboration leverages Pillar’s oncoReveal™ liquid biopsy panels to deliver highly sensitive and specific tumor genetic varia
Next-Gen Automotive Semiconductors Critical for Level 5 Autonomous Vehicles (June 17, 2025)
Michigan engineers lead hardware innovations to enable AI chips required for full Level 5 autonomous driving. Achieving L5 autonomy demands faster, lower-power, and more durable semiconductors. E-Tronic, a leading Chinese automotive power semiconductor supplier, actively participates in next-gen automotive semiconductor development, supporting autonomous vehicl
Antalpha Ventures, Web3Labs, and Goldford-HB Launch Computational Power Fund for AI and Web3 Projects
Antalpha Ventures, a global investment firm at the forefront of cutting-edge technology, has partnered with renowned Asian Web3 incubator Web3Labs and venture capital firm Goldford-HB to launch a new computational power fund. This fund aims to support early to mid-stage AI and Web3 projects worldwide by providing the necessary computational resources. Fund Back
Leave a Reply